Company intelligence / Profile preview

Paper Lantern

Dallas, Texas, United States

Ownership: Private
Development stage: Other

Overview

LP-300 Phase 2 trial shows 86% clinical benefit rate and 43% objective response rate in never-smokers with NSCLC; LP-184 Phase 1a advancing with Fast Track designations for GBM and TNBC, targeting enrollment completion June 2025; 12+ active programs developed using AI platform[1][2][3].

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody-drug conjugate
Industry: Biotech

Partnerships

Johns HopkinsNCI (joint paper)

Beyond the preview

Go deeper on Paper Lantern.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paper Lantern.

Explore the full profile